Finanzen von Aquestive Therapeutics, Inc. (AQST)AQSTAquestive Therapeutics, Inc.

Evaluating the bottom line, Aquestive Therapeutics, Inc. maintains a gross margin of 70.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.51%, while the net margin is -165.45%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AQST converts its operational activities into shareholder value.

In the context of the broader market, AQST competes directly with industry leaders such as AUTL and RGNX. With a market capitalization of $676.51M, it holds a leading position in the sector. When comparing efficiency, AQST's gross margin of 70.93% stands against AUTL's 57.61% and RGNX's 99.04%. Such benchmarking helps identify whether Aquestive Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Aquestive reported revenues of $13.8 million, a 38% increase from the previous year, but faced a net loss of $22.9 million, indicating financial struggles despite revenue growth.